Funding
Distalmotion raises US$150 million to take its DEXTER surgical robot into US outpatient centres
Swiss surgical robot maker Distalmotion closed a US$150 million Series G led by Revival Healthcare Capital on 18 November 2025 and named former Silk Road Medical chief executive Chas McKhann executive chairman. Johnson & Johnson's venture arm followed with a strategic investment in January 2026, and by August the FDA had cleared DEXTER for five procedures aimed at ambulatory surgery centres.